<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bian X</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>NIAID NIH HHS</funding><pagination>114171</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10019944</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>183</volume><pubmed_abstract>Antimicrobial resistance is a major global health challenge. As few new efficacious antibiotics will become available in the near future, peptide antibiotics continue to be major therapeutic options for treating infections caused by multidrug-resistant pathogens. Rational use of antibiotics requires optimisation of the pharmacokinetics and pharmacodynamics for the treatment of different types of infections. Toxicodynamics must also be considered to improve the safety of antibiotic use and, where appropriate, to guide therapeutic drug monitoring. This review focuses on the pharmacokinetics/pharmacodynamics/toxicodynamics of peptide antibiotics against multidrug-resistant Gram-negative and Gram-positive pathogens. Optimising antibiotic exposure at the infection site is essential for improvin</pubmed_abstract><journal>Advanced drug delivery reviews</journal><pubmed_title>Pharmacokinetics and pharmacodynamics of peptide antibiotics.</pubmed_title><pmcid>PMC10019944</pmcid><funding_grant_id>R01 AI146160</funding_grant_id><funding_grant_id>R01 AI132681</funding_grant_id><pubmed_authors>Chan HK</pubmed_authors><pubmed_authors>Feng M</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Bian X</pubmed_authors><pubmed_authors>Qu X</pubmed_authors><pubmed_authors>Nang SC</pubmed_authors><pubmed_authors>Tony Zhou Q</pubmed_authors><pubmed_authors>Bergen PJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pharmacokinetics and pharmacodynamics of peptide antibiotics.</name><description>Antimicrobial resistance is a major global health challenge. As few new efficacious antibiotics will become available in the near future, peptide antibiotics continue to be major therapeutic options for treating infections caused by multidrug-resistant pathogens. Rational use of antibiotics requires optimisation of the pharmacokinetics and pharmacodynamics for the treatment of different types of infections. Toxicodynamics must also be considered to improve the safety of antibiotic use and, where appropriate, to guide therapeutic drug monitoring. This review focuses on the pharmacokinetics/pharmacodynamics/toxicodynamics of peptide antibiotics against multidrug-resistant Gram-negative and Gram-positive pathogens. Optimising antibiotic exposure at the infection site is essential for improvin</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-26T13:09:56.523Z</modification><creation>2025-04-06T14:11:00.228Z</creation></dates><accession>S-EPMC10019944</accession><cross_references><pubmed>35189264</pubmed><doi>10.1016/j.addr.2022.114171</doi></cross_references></HashMap>